1 story in the last 7 days
The latest zydus news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks zydus across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Zydus Lifesciences shares fell 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity and strengthens Zydus's specialty and oncology supportive-care therapies pipeline.
Summaries by ByteBrief